|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity
Datamonitor, Sep 2010, Pages: 214
Introduction
Disease-modifying antirheumatic drugs (DMARDs) underpin the current management of rheumatoid arthritis. This will likely remain unchanged over the next decade. In spite of high costs, rheumatologists perceive there will be an increased penetration of biologic therapies in patients of all severities by 2015, with competition between biologic classes intensifying at earlier lines of therapy.
Scope
- Snapshot of the current rheumatoid arthritis market based on a survey of 183 rheumatologists, supported with views from key opinion leader interviews
- Robust epidemiology forecasts for the prevalence of rheumatoid arthritis in the seven major markets, from 2009 through to 2019
- Overview of treatment options at the class, molecule and brand level, as well as treatment trends by line of therapy and treatment outcome analysis
- Assessment of select brands used in rheumatoid arthritis treatment, including biologics and the scope for novel small molecule DMARDs
Highlights
In 2010, traditional DMARDs are the foundation of drug therapy in rheumatoid arthritis and will remain at the core of treatment going forward. Methotrexate is the most highly utilized DMARD across all disease severities and will stay as gold-standard owing to its ease of administration, manageable side-effect profile, good efficacy and low cost.
Rheumatologists predict a significant rise in the number of patients receiving biologic therapy across each severity by 2015. There will also be a greater drive from physicians to use non-TNF biologics much earlier in the treatment algorithm, with over a third of first-line patients expected to receive such therapies in the next five years
The future position in the treatment algorithm of novel, oral, small molecule DMARDs, such as tasocitinib (CP-690,550; Pfizer), will decide uptake and sales success. The majority of physicians expect to use these agents in methotrexate-failure patients and prior to a biologic, potentially delaying the move to biologics.
Reasons to Purchase
- Target rheumatologists more effectively, through an understanding of their prescribing behavior and key factors that influence decision making
- Validate new product forecasting based on diagnosis, therapy trends and the likely rate of uptake for new products utilizing physician perception
- Estimate the size of the rheumatoid arthritis population using the interactive country-specific treatment trees that incorporate patient numbers
Customers who bought this item also bought
Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market
Rheumatoid Arthritis Market Forecast
Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies
U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
Special Report: The Autoimmune Biologics Pipeline-A Competitive Review
Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis
Will Emerging Agents Disrupt the Psoriatic Arthritis Market?
Juvenile Idiopathic Arthritis (JIA): KOL Insights on Treatment Practices and Unmet Needs
Rheumatoid Arthritis Therapeutics Market in Thailand
|
|
|
|
